Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Technological Barriers to Telehealth Use for Patients With Cancer
Significant disparities in technological knowledge and access to telehealth exist among cancer patients and are largely associated with demographic characteristics.
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Real-World Use of Pembrolizumab Plus Chemotherapy for NSCLC
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than those who received chemotherapy alone.
